{"id":"NCT02576574","sponsor":"EMD Serono Research & Development Institute, Inc.","briefTitle":"Avelumab in First-line NSCLC (JAVELIN Lung 100)","officialTitle":"A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-29","primaryCompletion":"2021-12-06","completion":"2024-01-29","firstPosted":"2015-10-15","resultsPosted":"2023-01-04","lastUpdate":"2025-01-31"},"enrollment":1214,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["First Line Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"Avelumab","otherNames":["Anti-PD-L1","MSB0010718C"]},{"type":"DRUG","name":"Pemetrexed","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Gemcitabine","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Avelumab Weekly","otherNames":["Anti-PD-L1","MSB0010718C"]}],"arms":[{"label":"Avelumab Biweekly","type":"EXPERIMENTAL"},{"label":"Avelumab Weekly","type":"EXPERIMENTAL"},{"label":"Chemotherapy","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) participants with Programmed death ligand 1+ (PD-L1+) tumors.","primaryOutcome":{"measure":"Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)","timeFrame":"Time from date of randomization up to data cutoff (assessed up to approximately 71.5 months)","effectByArm":[{"arm":"Avelumab Biweekly","deltaMin":8.4,"sd":null},{"arm":"Chemotherapy","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0070"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":2},"locations":{"siteCount":349,"countries":["United States","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","China","Colombia","Croatia","Cyprus","Czechia","Denmark","Estonia","France","Germany","Greece","Hungary","Ireland","Israel","Italy","Japan","Lebanon","Lithuania","Netherlands","New Zealand","Peru","Poland","Portugal","Romania","Russia","Serbia","Singapore","Slovakia","South Africa","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["37748693"],"seeAlso":["https://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR%20100070-005","https://medical.emdserono.com/en_US/home.html"]},"adverseEventsSummary":{"seriousAny":{"events":181,"n":361},"commonTop":["Anaemia","Nausea","Decreased appetite","Fatigue","Asthenia"]}}